Some Covid vaccines may be “better suited” for certain age groups or for use as boosters, a scientist working on the Novavax trial said today.
Professor Paul Heath, chief investigator of the Novavax trial, said the wide range of vaccines used to help fight the pandemic would help leaders “fine-tune the immunization schedule.”
He said over time some vaccines might prove to be “better suited” for certain age groups while others might be more suitable for booster doses.
The scientist made the comments when asked on Sky News why it was important to have a lot of different vaccines.
Professor Heath said: “Obviously, because there are so many people who need to be vaccinated, we need to have a huge supply of vaccines in order to fully immunize our population, which I think is the key. fundamental reason.
“There are other things that can be shown between the different vaccines at the end of the day.
“So we can show, for example, that certain vaccines are more appropriate for certain groups of elderly people, for those with underlying health problems, and so on.
“I think over time we may define different groups for different vaccines.”
Professor Heath, who is also director of the Vaccine Institute at St George’s, University of London, added: ‘We are looking at, for example, vaccinating adolescents and children, we are looking at and actually vaccinating pregnant women and there may be studies show that some vaccines may be better suited to different groups.
“So having this range of vaccines using a range of different technologies will ultimately allow us to refine the vaccination program.
“The next step will of course be the booster doses.
“We’ve already heard over the weekend a proposal that booster doses will be considered and possibly implemented later this year and different vaccines may be better suited to be booster doses.
“So again, having a whole range of different vaccines using different vaccine technologies allows us to refine the program that we have right now.”
It comes after the government struck a deal with pharmaceutical giant GlaxoSmithKline (GSK) to manufacture up to 60 million doses of the Novavax coronavirus vaccine.
Doses will undergo their ‘fill and finish’ stage at a Barnard Castle facility in North East England from May. This is the stage of vaccine manufacturing completion during which vials are prepared and packaged for distribution.
The company said it was 86% effective against the Kent variant and 96% effective in preventing cases caused by the original strain of the coronavirus.
The jab also offers 100% protection against serious illnesses, including all hospitalizations and deaths, according to the results of the phase three trial in the UK.
The new vaccine is now awaiting approval from the Medicines and Health Products Regulatory Agency (MHRA).
Boris Johnson said the agreement between GSK, Novavax and the UK government’s vaccine task force “will further boost the deployment of our vaccines.”
He added: “The Vaccines Task Force has worked hand in hand with companies to successfully deliver vaccines across the UK and this agreement will continue to support our approach.
“We remain on track to deliver a first vaccine to everyone over 50 by April 15, and to all adults by the end of July, and I want to once again encourage everyone to show up for a vaccine when called. ”